Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 2, 2007, Pages 237-246

  Liu, Guozheng ^a   Dou, Shuping ^a   He, Jiang ^a   Liu, Xinrong ^a   Rusckowski, Mary ^a   Hnatowich, Donald J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Drug delivery; Immunodetection; Pretargeting; Technetium; Tumor

Indexed keywords

CARCINOEMBRYONIC ANTIBODY; COMPLEMENTARY PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER TC 99M; MORPHOLINE DERIVATIVE; OLIGOMER; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER MN14 ANTIBODY CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG TUMOR LEVEL; ISOTOPE LABELING; KIDNEY; MOUSE; NONHUMAN; PREDICTION; RADIOISOTOPE DISTRIBUTION; TUMOR; TUMOR MODEL; TUMOR VOLUME;

ALGORITHMS; ANIMALS; CELL LINE, TUMOR; COLONIC NEOPLASMS; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; MODELS, BIOLOGICAL; MORPHOLINES; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 33846413002     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0222-3     Document Type: Article

References (15)

1. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med 1987;28:1294-302.
2. Goodwin DA, Meares CF, McTigue M, et al. Rapid localization of haptens in sites containing previously administrated antibody for immunoscintigraphy with short half-life tracers [abstract]. J Nucl Med 1986;27(suppl):959.
3. Kuijpers WH, Bos ES, Kaspersen FM, Veeneman GH, van Boeckel CA. Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: a novel approach for two-step radioimmunotherapy of cancer. Bioconj Chem 1993;4(1):94-102.
4. Goldenberg DM, Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, et al. Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 2003;30:777-80.
5. Paganelli G, Chinol M. Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 2003;30:773-6.
6. 99mTc-labeled morpholino, a DNA analog. J Nucl Med 2002;43:384-91.
7. 99mTc-morpholinos in mice. Q J Nucl Med 2002;46:233-43.
8. 99mTc-labeled morpholino oligomers. Antisense Nucleic Acid Drug Dev 2002;12:393-8.
9. Liu G, He J, Dou S, Gupta S, Vanderheyden J-L, Rusckowski M, et al. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake. Eur J Nucl Med Mol Imaging 2004;31:417-24.
10. Liu G, He J, Dou S, Gupta S, Rusckowski M, Hnatowich DJ. Further investigations of morpholino pretargeting in mice - establishing quantitative relations in tumor. Eur J Nucl Med Mol Imaging 2005;32:1115-23.
11. Yuan F, Baxter LT, Jain RK. Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res 1991;51:3119-30.
12. Sung C, van Osdol WW. Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding. J Nucl Med 1995;36:867-76.
13. 3 for technetium-99m labeling of DNA. Nucl Med Biol 1997;24:425-32.
14. 188Re at high labeling efficiency and specific radioactivity for tumor pretargeting. Appl Radiat Isot 2006;64:971-8.
15. He J, Liu G, Dou S, Gupta S, Rusckowski M, Hnatowich DJ. An improved method for covalently conjugating morpholino oligomers to antitumor antibodies [abstract]. J Nucl Med 2005;46:350P.